The in Vivo Expansion Rate of Properly Stimulated Transferred Cd8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor.
From: Clinical Research Center, National Cancer Institute/NIH, Building CRC, Bethesda, MD 20892, USA.
Cancer research
- Publish Date: Jan 2006
- ISSN: 0008-5472
- Volume: 66
- Issue: 2
- Pages: 1132-8
- Medium: Print
- Language: English
- Citation (JAMA): Hwang Leroy N, Yu Zhiya, Palmer Douglas C, et al. The in Vivo Expansion Rate of Properly Stimulated Transferred Cd8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor.. Cancer Res. Jan 2006;66:1132-8
Abstract
It has been hypothesized that rapidly dividing tumor cells can outpace adoptively transferred antitumor lymphocytes when tumors are large. However, this hypothesis is at odds with clinical observations indicating that bulky tumors can be destroyed by small numbers of adoptively transferred antitumor T cells. We sought to measure the relative growth rates of T cells and tumor cells in a model using transgenic CD8(+) T cells specific for the gp100(25-33) H-2D(b) epitope (called pmel-1) to treat large, well-established s.c. B16 melanoma. We tested the effect of the immunization using an altered peptide ligand vaccine alone or in combination with interleukin-2 (IL-2) by analyzing the kinetics of T-cell expansion using direct enumeration. We found that pmel-1 T cells proliferated explosively during a 5-day period following transfer. Calculations from net changes in population suggest that, at the peak of cell division, pmel-1 T cells divide at a rate of 5.3 hours per cell division, which was much faster than B16 tumor cells during optimal growth (24.9 hours per cell division). These results clearly indicate that the notion of a kinetic “race” between the tumor and the lymphocyte is no contest when adoptively transferred cells are stimulated with immunization and IL-2. When appropriately stimulated, tumor-reactive T-cell expansion can far exceed the growth of even an aggressively growing mouse tumor.
Mesh Headings (Keywords): Animals, CD8-Positive T-Lymphocytes, Cancer Vaccines, Cell Proliferation, Immunization, Immunotherapy, Adoptive, Interleukin-2, Kinetics, Ligands, Melanoma, Mice, Mice, Inbred C57BL, Mice, Transgenic, Skin Neoplasms
Check for Full Text / PubMed Unique Identifier (PMID): 16424050
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.